The renin-angiotensin system (RAS) remains a cornerstone of cardiovascular and renal physiology, orchestrating vital aspects of blood pressure regulation and fluid-electrolyte balance. At the heart of ...

Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center. Two new studies have been published that further focus attention on how the renin–angiotensin ...

A new viewpoint article published in the journal JAMA Network in April 2020 deals with the use of a widely used category of cardiovascular medications in COVID-19 patients with hypertension, diabetes, ...

Angiotensin-converting enzyme inhibitors or angiotensin II type 1 receptor antagonists have become an important tool for the treatment of hypertension and its cardiovascular complications. Inhibition ...

A potential association between the use of angiotensin-receptor blockers (ARBs) and angiotensin-converting–enzyme (ACE) inhibitors and the risk of coronavirus disease 2019 (Covid-19) has not been well ...

Renin–angiotensin system (RAS) inhibitors — including angiotensin-converting–enzyme (ACE) inhibitors and angiotensin-receptor blockers (ARBs) — slow the progression of mild or moderate chronic kidney ...

The renin-angiotensin system (RAS) becomes active at low blood pressure and forms angiotensin II, a hormone that causes blood vessels to constrict, causing blood pressure to rise again. The enzyme ...

Profs Ravi Acharya and Edward Sturrock review the historical foundation, present landscape and future clinical promise of ACE inhibition.

Anyone who is taking a diuretic and a renin-angiotensin system (RSA) inhibitor for high blood pressure should be cautious about also taking ibuprofen, according to new research. Anyone who is taking a ...

Please provide your email address to receive an email when new articles are posted on . RAS blockers had similar mortality benefit by race in patients with HFrEF. RAS blockers improved HF ...